Navigation Links
Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
Date:2/25/2013

olumes of a medication under the skin and may result in faster administration times versus intravenously (IV) administered MabThera.
  • MabThera Positive Trials: Announced positive results from Roche's SABRINA and SparkThera studies, which showed that a fixed dose of MabThera can be administered subcutaneously, potentially allowing patients to spend less time in infusion centers receiving their MabThera treatment. Specifically, the studies showed that subcutaneous injection resulted in non-inferior MabThera concentrations in the blood compared with standard IV infusion.
  • Fourth Quarter and Year End 2012 Financial ResultsThe net loss for the fourth quarter of 2012 was $4.4 million, or $0.04 per share, compared with a net loss for the fourth quarter of 2011 of $18.4 million, or $0.18 per share. The net loss for the year ended December 31, 2012 was $53.6 million, or $0.48 per share, compared to a net loss of $19.8 million, or $0.19 per share for the comparable period in 2011.

  • Revenues for the fourth quarter of 2012 were $21.8 million, compared to $2.4 million for the fourth quarter of 2011. Revenues in the fourth quarter of 2012 included license fees revenue from Pfizer of $9.5 million and a milestone payment from Roche of $4 million.
  • Research and development expenses for the fourth quarter of 2012 were $18.6 million, compared with $14.9 million for the fourth quarter of 2011. The increase was due primarily to an increase in manufacturing activities to support potential launches from our collaborators.
  • Selling, general and administrative expenses for the fourth quarter of 2012 were $7.0 million, compared to $5.9 million for the fourth quarter of 2011.
  • Cash and cash equivalents were $99.9 million as of December 31, 2012, which includes net proceeds of $29.7 million from a term loan with Oxford Finance and Silicon Vall
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
    2. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
    3. Halozyme to Host Third Quarter Financial Results Conference Call
    4. Halozyme Reports Second Quarter 2012 Financial Results
    5. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
    6. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
    7. Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
    8. Halozyme Reports First Quarter 2012 Financial Results
    9. Halozyme to Host First Quarter 2012 Financial Results Conference Call
    10. Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
    11. Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... ANGELES , Aug. 29, 2014  Chuma ... both financing alternatives and turnkey support services for ... announce that FINRA processed and approved the Company,s ... 29, 2014, CannaMed Corporation will be known as ... change was accomplished through a merger with the ...
    (Date:8/29/2014)... The Competitive Intelligence (CI) function is evolving ... leaders who adjust will succeed, and those who don,t ... Practices, LLC study CI leaders from 32 biopharmaceutical organizations ... - Use secondary research whenever possible - it,s effective, ... Internal staff who are creative thinkers provide the CI ...
    (Date:8/29/2014)... 2014 Pomerantz LLP has filed a class ... (NASDAQ: EDAP ) and certain of its ... Court, Southern District of New York ... a class consisting of all persons or entities who ... 30, 2014, inclusive (the "Class Period"). This class action seeks ...
    Breaking Medicine Technology:CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3
    ... Inc. (pronounced dot decimal), an innovative manufacturer of patient-specific ... 510(k) clearance from the FDA to market electron apertures ... now available to radiation oncology centers across the U.S. ... known as electron ,cutouts, by radiation therapy departments -- ...
    ... - Digital issue looks inside the minds, lives ... Journal of Emergency Medical Services ( JEMS ) ... issue featuring first-person accounts of responders who were thrust into ... terrorists invaded their response districts - and their lives - ...
    Cached Medicine Technology:Florida Medical Device Manufacturer Announces New Product Release for Radiation Therapy 2Out of the Darkness 2Out of the Darkness 3
    (Date:9/1/2014)... The Outlier Series announced the next ... content from one of the exceptional women featured in ... Game Changers . The title of the upcoming mini ... Jenny McClendon . McClendon is currently a full-time physician’s ... star of WeTV show, Raising Sextuplets. , Jenny was ...
    (Date:9/1/2014)... Psychogenic Non-epileptic Seizures (PNES), also known as non-epileptic ... have devastating effects on those who develop it. These ... are not produced by electrical anomalies in the brain ... that the numbers of persons suffering PNES may be ... , Dr. Lorna Myers, Director of the Northeast Regional ...
    (Date:8/31/2014)... (PRWEB) August 31, 2014 The FDA ... Nutrition Facts label. If adopted, the proposed changes would ... addition of “added sugars” on the label, and a ... to keep “added sugars” off the label. NutriGold fully ... consumers make healthier food choices. “After 20 years, it's ...
    (Date:8/31/2014)... Mesa, AZ (PRWEB) August 31, 2014 ... in Mesa, Arizona, prescribes sublingual immunotherapy to help his ... includes tree nut allergies. Dr. Agren said that it ... nut-based foods and, in many cases, restored peace of ... can lead to a host of symptoms, including rashes, ...
    (Date:8/31/2014)... Orem, UT (PRWEB) August 31, 2014 ... a number of states have proposed legislation to require ... so consumers can make informed purchasing decisions that affect ... As an industry leader advocating for stringent measures to ... launch of its “Information, Communication, Engagement” (I.C.E.) initiative with ...
    Breaking Medicine News(10 mins):Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 2Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 3Health News:The Northeast Regional Epilepsy Group (NEREG) Offers First Conference on Psychogenic Non-epileptic Seizures (PNES) on September 20, 2014 in New Jersey 2Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 2Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 3Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 4Health News:Family Allergy Clinic Announces Q4 2014 Release of Oral Drops for Tree Nut Allergies 2Health News:Family Allergy Clinic Announces Q4 2014 Release of Oral Drops for Tree Nut Allergies 3Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 2Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 3
    ... Annual Scientific Meeting: Nearly 5,300 physicians, scientists and ... IR" showcases the exciting ways that interventional radiologists ... on new research related to multiple sclerosis and ... From Science to Practice." There will be debates ...
    ... Feb. 9 (HealthDay News) -- Zebras evolved from all ... distract them from feeding, a new study contends. ... black and white stripes are the least-attractive hide pattern ... horseflies. The researchers found that horseflies are drawn ...
    ... a study to be presented today at the Society ... in Dallas, Texas, researchers will report findings that women ... appear to know little about the risks and benefits ... of labor to attempt a vaginal delivery, and that ...
    ... including the mapping of the genomes of more than ... base pairs of sequence data. The leading scientific journal ... the scientific breakthroughs of 2011. Large-scale genome sequencing is ... agricultural research. Henry Yang, Executive Managemer of BGI, ...
    ... WEDNESDAY, Feb. 8 (HealthDay News) -- Middle-school kids who participate ... than other kids, new research finds. Yet, students with ... apparent influence of peers is more pronounced among girls. ... smoking behavior of others even though there might be a ...
    ... Researchers at Virginia Commonwealth University Medical Center,s VCU ... Center (Richmond, VA) and Old Dominion University (Norfolk, ... 1 protein (WT1) results in downregulation of CD97 ... reduces the characteristic invasiveness exhibited by glial tumor ...
    Cached Medicine News:Health News:Media alert: Society of Interventional Radiology's 37th Annual Scientific Meeting 2Health News:Bug Bites May Have Caused Zebras' Stripes 2Health News:Study finds pregnant women with prior cesarean choose the delivery method preferred by their doctor 2Health News:VIB and BGI organize joint genomics meeting, Feb. 15, 2012, Belgium 2Health News:VIB and BGI organize joint genomics meeting, Feb. 15, 2012, Belgium 3Health News:CD97 gene expression and function correlate with WT1 protein expression and glioma invasiveness 2Health News:CD97 gene expression and function correlate with WT1 protein expression and glioma invasiveness 3
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    Medicine Products: